Potential Biomarker B. Microti Babesiosis Cases
Michael Lum, et al., published “Procalcitonin as a Potential Biomarker in the Study of Babesiosis Caused by B. microti” in Pathogens on October 23, 2022. Thirty-three acute babesiosis cases from 2012 through 2019 were collected retroactively from Long Island-based Stony Brook University Hospital (SBUH) and Stony Brook South Hampton Hospital (SHH). The cases were cross-referenced for necessary ICU admission, and procalcitonin levels were measured using BRAHMS Elecsys assay at SBUH and BRAHMS Architect assay at SHH.
Results of the study indicate that there is a direct link between procalcitonin and parasitemia values. Moreover, procalcitonin may aid in verifying the measure of disease severity. These results show potential for a direct correlation between procalcitonin and the parasitemia percentage as well as possible prognostic capabilities, suggesting that procalcitonin could have potential as a biomarker in cases of human babesiosis.
For more information: